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ABSTRACT
BDNF is a neurotrophic factor synthesized in the central nervous system (CNS) and the periphery. It passes
through the brain-blood barrier. Peripheral BDNF can exert a trophic effect in the CNS and different plasma
BDNF levels in schizophrenia, depression and bronchial asthma could contribute to negative correlation be-
tween these diseases. The aim of the present study was to assess peripheral BDNF levels in these diseases and
to relate them to their estimated comorbidity. Plasma BDNF was assessed by immunoassay while disease inci-
dence rate and comorbidity was assessed by database retrieval in patients suffering from schizophrenia, de-
pressive episode and bronchial asthma. A lower plasma BDNF level was observed in patients with
schizophrenia and depressive episode compared to those suffering from bronchial asthma and a negative
comorbidity between diseases was registered. These observations support the important role of BDNF in the
pathogenesis of schizophrenia and depression and can explain their negative comorbidity with bronchial
asthma.
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INTRODUCTION
There are studies and hypotheses which link the
pathogenesis of schizophrenia with the concentration and ac-
tivity of neural trophic factors like BDNF, NT-3, etc. . There
is abundant evidence of the relationship between
neurotrophins and schizophrenia. BDNF is, probably, of
highest importance for the genesis of schizophrenia and its
polymorphic variants. There is also a point of view which
states that BDNF is not single factor but rather is intercon-
nected with NT-3, i.e. neurotrophins have complex influence
on the brain processes. There are similar observations con-
cerning the affective disorders and depressive episodes with
psychotic symptoms in the premises of bipolar affective dis-
order (BAD) and recurrent depressive disorder (RDD).
Evidence for BDNF involvement in the pathogenesis of
schizophrenia comes from observations that its level is
lower than that in healthy controls even before clinical pre-
sentation of the first disease episode . A lower BDNF level
has been consistently observed during the disease course,
too . It is considered that the deficiency of this major trophic
factor disrupts an array of brain processes associated with
neuronal plasticity, progenitor migration, apoptosis and
mediator function . This mechanism is, probably, also valid
for depressive disorders considering the model for common
genesis of these diseases.
Bronchial asthma is a disease associated with a higher BDNF
level .Thereareobservations that the levelof thisneurotrophic
factor increases progressively during the period of chronic al-
lergic inflammation . Neurotrophinsare produced byepithelial
cells in the lung and the airways and these have been consid-
ered as the ‘big source of NGF and BDNF’.
The role of neurotrophins in bronchial asthma is related to
their effects on the peripheral nervous system and the ac-
tivity of cells of the immune system within the airways.
BDNF is capable of passing through the blood-brain barrier
and, in this way, the peripheral level would affect processes
within the central nervous system (CNS).
Considering the dissociation of peripheral BDNF level in
these diseases we aimed at studying the comorbidity of
bronchial asthma and schizophrenia as well as of bronchial
asthma and depressive episode and examining the level of
BDNF in peripheral blood of bronchial asthma, schizo-
phrenia and depressive episode.
MATERIAL AND METHODS
Patients
Comorbidity of schizophrenia and bronchial
asthma
The study was conducted in the information database of St.
Marina University Hospital of Varna during the period
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from 2002 till 2009. This is the only hospital in Varna re-
gion with specialized clinics of allergic and psychiatric dis-
eases and thus it is expected that the majority of patients
with these diseases are registered in the information
database.
The records of 1891 schizophrenia patients were checked
for comorbidity with bronchial asthma, those of 1591 bron-
chial asthma patients - for comorbidity with schizophrenia,
and those of 2510 depressive syndrome patients - for
comorbidity with bronchial asthma.
The psychiatric diseases were classified according to
ICD-9 and ICD-10. In order to simplify the data analysis all
the diagnostic codes were translated to ICD-10. The diag-
nostic codes according to ICD-10 were the following:
	 patients with schizophrenia were classified as ‘paranoid
schizophrenia’ (F20.0) according to ICD-10;
	 patients with depressive syndrome were classified as
‘recurrent depressive disorder’ (F33), ‘bipolar affective
disorder’ (F31), ‘depressive episode - moderate severity
depressive episode’ (F32.1) and ‘severe depressive
episode with psychotic symptoms’ (F32.3) were
aggregated in ‘depressive syndrome’ according to
ICD-10
	 patients with bronchial asthma were classified as
‘nonatopic bronchial asthma’ (J45) according to
ICD-10.
BDNF levels in blood plasma
Blood plasma BDNF levels of were examined in the fol-
lowing groups:
1. a total of 31 patients with schizophrenia, 15 males at a
mean age of 31 years (range 18-48 years) and 16
females at a mean age of 37,4 years (range, 18-48
years). At the moment of recruiting, the patients did not
present with any acute or exacerbated chronic somatic
disease. All of them were treated with standard
antipsychotic therapy consisting of second-generation
antipsychotic drugs. The patients were sampled for the
period of disease relapse due to discontinuation of
therapy and after at least 20 days of treatment and
clinical remission;
2. ten female patients depressive syndrome at a mean age
of 51,2 years (range, 38-60 years) were sampled for the
period of disease relapse and clinical remission;
3. ten patients with bronchial asthma, 8 females at a mean
age of 46,7 years (range, 29-73 years) and two males at
a mean age of 32,7 years. The patients were sampled
once for the subacute period and underwent a standard
antiasthmatic therapy;
4. a control group consisting of 10 healthy volunteers, 4
males aged between 33 and 42 years and 6 females
aged between 34 and 38 years.
Methods
Data were retrieved from the aforementioned information
database for the period from 2002 till 2011 and statistically
aggregated by its specialized software. Patients’ records
were accessed by patient’s name and unique ID.
BDNF concentration (in pg/mL) was estimated in blood
plasma. For separation of blood plasma EDTA
anticoagulated blood was collected in vacuum closed col-
lection system (Vacuette, Greiner Bio One). Blood was
transported on ice and plasma was separated within 30
minutes after collection by centrifugation at 1000 g for 15
min. Blood plasma samples were stored at -80°C until ana-
lyzed. Analysis of BDNF concentration was performed us-
ing Quantikine Human BDNF Immunoassay ELISA kit,
catalog number DBD00 (R&D Systems) according to
manufacturer’s instructions.
Statistical data processing was done by using the dispersion
analysis (ANOVA), multiple comparison Mann-Whitney
non-parametric test and percent distribution.
RESULTS
We established that only 4 (0,25%) of 1591 patients with
bronchial asthma presented with accompanying schizo-
phrenia while only 4 (0.21%) of 1891 with schizophrenia
presented with accompanying bronchial asthma. These
four patients were the same in both groups. Some 29
(1,15%) of 2510 patients with depressive syndrome pre-
sented with accompanying bronchial asthma. It is evident
that both comorbidities, i. e. of bronchial asthma and
schizophrenia, on the one hand, and bronchial asthma and
depressive syndrome, on the other hand, are lower than the
expected incidence rate in Bulgaria. The results of the
disease prevalence are shown in Table 1.
There are statistically significant difference in the variance
between all the groups tested (ANOVA, p<0,05) and inter-
group differences (Mann-Whitney test) in BDNF concen-
trations between: i) the patients with schizophrenia (in re-
lapse) compared to those with bronchial asthma (p<0,05);
ii) the patients with bronchial asthma compared to those
with depressive syndrome (in relapse) (p<0,05), and iii) the
patients with depressive syndrome (in relapse) compared to
the control group (p<0,01).
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BA and Sch BA BA and Sch / BA%
n=4 n=1591 0,25%
BA and Sch Sch BA and Sch / Sch%
n=4 n=1891 0,21%
BA and RDD RDD BA-RDD / RDD%
n=29 n=2510 1,15%
BA and RDD BA BA-RDD / BA%
n=29 n=1591 1,82%
Table 1. Comorbidity of bronchial asthma (BA),
schizophrenia (Sch) and recurrent depressive disorder
DISCUSSION
The estimated comorbidity incidence rate of bronchial
asthma and schizophrenia supports a previous study of ours
showing an extremely low comorbidity between these two
diseases (17). These results are contradictory to other ones
in the literature available. A higher than expected
comorbidity of bronchial asthma and schizophrenia was es-
tablished . However, in their study bronchial asthma is in-
cluded as a part of atopic diseases while we included the
nonatopic infectious-allergic form of this disease.
We reveal a lower than expected comorbidity incidence of
depressive syndrome and bronchial asthma, too. When in-
terpreting this fact one should have in mind that many pa-
tients with bronchial asthma have depressive experiences
because of psychogenic causes and antiasthmatic treat-
ment. In our study, the patients with ‘endogeneous depres-
sion’ were included only.
Our results concerning the BDNF blood plasma levels are
concordant with the literature available, e.g. about higher
BDNF levels in bronchial asthma patients than in patients
with schizophrenia and depression . Besides BDNF con-
centrations in the patients with bronchial asthma are higher
than in the control group. These results are demonstrated on
Fig. 1.
The outlined negative comorbidity of bronchial asthma and
schizophrenia as well as of bronchial asthma and depres-
sion proved in epidemiological studies along with the
marked differences in BDNF blood plasma levels in these
diseases reflect, probably, one of the milestones of the
pathogenesis of schizophrenia and depressive syndrome.
This statement could be viewed in two aspects: on one
hand, the lower BDNF concentration in the CNS could
cause disturbed neuronal plasticity, progenitor migration
and apoptosis, and on the other hand, by its concentration,
BDNF could exert different effects due to its different poly-
morphic variants. These variants would not have the effect
of the wild type of BDNF. In this way, these aforemen-
tioned mechanisms of neuronal plasticity, apoptosis and
progenitor migration, mainly in the regions associated with
schizophrenia development could prove biologically inef-
fective and contribute to the development of schizophrenia.
Similar arguments could be drawn to the depressive syn-
drome, i. e. depressive episode with psychotic symptoms
and depressive episode in the premises of bipolar affective
disorder and recurrent depressive disorder.
This predication correlates with the idea that the higher
BDNF level in bronchial asthma could possess a
neuroprotective effect in the CNS and prevent the develop-
ment of schizophrenia in some cases. This is a possible ex-
planation of the established lower than expected
comorbidity of bronchial asthma and schizophrenia and of
bronchial asthma and depressive syndrome, respectively.
The similarity between the lower BDNF level in schizo-
phrenia and depressive syndrome compared to healthy in-
dividuals is an indirect evidence of the existence of com-
mon mechanisms in the pathogenesis of schizophrenia and
‘psychotic’ depressive episode.
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